- News Releases
Researchers at Mayo Clinic in Florida have identified an enzyme that could represent a powerful new tool for combating Alzheimer’s disease. Alzheimer’s is the most common memory disorder in the United States and affects more that 5.5 million people.
The enzyme — known as BACE2 — destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease. The discovery is interesting because BACE2 is closely related to another enzyme, known as BACE1, involved in producing beta-amyloid. Read entire news release: Dr. Leissring Alzheimer's
Sound bites with lead author Malcolm Leissring, Ph.D., are available in the downloads.
Expert title for broadcast cg: Dr. Malcom Leissring, Mayo Clinic Neuroscientist
Findings are published online in Molecular Neurodegeneration
Memorial Day weekend is the unofficial kickoff to summer. And picnics can be a fun way to start the summer season. But improper handling of ...
A hemangioma, also known as a strawberry birthmark, is a bright red birthmark that shows up in the first or second week of life. It ...
DEAR MAYO CLINIC: I'm training for my first long-distance race, and I want to be safe on my runs. Unfortunately, due to where I live, the ...